Acrivon Therapeutics, Inc. ACRV
We are a clinical-stage biopharmaceutical company discovering and developing precision medicines utilizing our proprietary Generative Phosphoproteomics Acrivon Predictive Precision Proteomics, or AP3, platform designed to quantify compound-specific, drug-regulated pathway activity levels inside the intact cell in an unbiased manner, yielding terabytes of proprietary data and delivering rapid, actionable insights. Our company name, Acrivon, is derived from Greek for "accurate" or "precise". We chose it to embody how our AP3 platform can, among other highly actionable discovery and development applications, accurately match our therapies with patients who will benefit. Recently approved precision oncology treatments, such as kinase inhibitors, have transformed the cancer treatment landscape, and while the therapeutic benefit of these agents has provided significant benefit to patients, these precision oncology treatments unfortunately only address the less than 10% of patients with cancers that harbor certain easily-identifiable genetic mutations. Our approach is designed to overcome the limitations of genetics-based precision medicine. We do this by using our precision medicine platform, AP3, to discover and develop our pipeline of innovative oncology drug candidates. AP3 is engineered to measure compound-specific effects on the entire tumor cell protein, signaling network and drug-induced resistance mechanisms in an unbiased manner and is modality and disease agnostic.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D | $60.0M | $64.0M | $46.0M | $23.9M | — | — |
| SG&A | $24.1M | $25.2M | $21.1M | $8.7M | — | — |
| Total operating expenses | $84.1M | $89.2M | $67.1M | $32.7M | $16.2M | — |
| Operating income | -$84.1M | -$89.2M | -$67.1M | -$32.7M | -$16.2M | — |
| Pre-tax income | -$77.8M | -$80.4M | — | — | — | — |
| Income tax | $0 | — | — | — | — | — |
| Net income | -$77.9M | -$80.6M | -$60.4M | -$31.2M | -$16.2M | — |
| EPS, basic | -2.02 | -2.38 | -2.74 | -7.56 | -9.32 | — |
| EPS, diluted | -2.02 | -2.38 | -2.74 | -7.56 | -9.32 | — |
| Shares, diluted (wtd. avg.) | 38.5M | 33.8M | 22.1M | 4.1M | 1.7M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $41.5M | $39.8M | $36.0M | $29.5M | $99.6M | — |
| Short-term investments | $77.1M | $139.7M | $91.4M | $98.2M | — | — |
| Total current assets | $120.4M | $181.6M | $129.7M | $132.1M | $100.4M | — |
| Property, plant and equipment | $4.9M | $4.5M | $3.5M | $2.1M | $290.0K | — |
| Total assets | $129.7M | $196.6M | $138.3M | $181.2M | $106.6M | — |
| Accounts payable | $2.3M | $758.0K | $5.0M | $904.0K | $964.0K | — |
| Total current liabilities | $15.7M | $17.2M | $13.3M | $6.5M | $2.9M | — |
| Total liabilities | $17.2M | $19.8M | $17.1M | $10.8M | $7.9M | — |
| Retained earnings | -$274.9M | -$197.0M | -$116.4M | -$56.0M | -$24.9M | — |
| Total equity | $112.5M | $176.8M | $121.2M | $170.5M | -$23.8M | -$8.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$63.7M | -$65.7M | -$42.6M | -$30.1M | -$14.0M | — |
| Depreciation and amortisation | $1.4M | $1.0M | $536.0K | $364.0K | $37.0K | — |
| Stock-based compensation | $14.7M | $14.3M | $11.6M | $2.2M | $497.0K | — |
| Capital expenditure | $1.7M | $2.8M | $1.3M | $2.2M | $238.0K | — |
| Investing cash flow | $66.1M | -$51.8M | $50.7M | -$141.7M | -$238.0K | — |
| Financing cash flow | -$749.0K | $121.0M | -$1.6M | $101.7M | $112.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-115123.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Net income | — | -$16.2M | -$31.2M | -$60.4M | -$80.6M | -$77.9M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Regulation FD disclosure Item 7.01
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Regulation FD disclosure Item 7.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |